Incanthera plc
The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months.
The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
| Symbol | Ccy Code | Bid | Ask | Mid | Previous Close | Volume | Last Traded |
|---|---|---|---|---|---|---|---|
| INC | GBX | 13 | 13.3 | 13.15 | 13.15 | 100 | 15.06.21 |
MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.
Financial Information
| 31.03.21 | |
|---|---|
| Enterprise Value | £11.33m |
| EV/EBITDA | (11.15) |
| EV/EBIT | (11.15) |
| PE Ratio | (12.52) |
| PEG | 158.54% |
| Dividend Yield | - |
| Free Cash Yield | (6.88)% |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
31.03.21 (£'000) |
|
|---|---|---|---|
| Income Statement | |||
| Revenue | - | - | - |
| Operating Income (EBIT) | (1,848) | (1,226) | (1,016) |
| Net Income | (1,988) | (1,128) | (905) |
| Balance Sheet | |||
| Cash | 176 | 392 | 957 |
| Total Debt | - | - | - |
| Total Liabilities | 223 | 177 | 165 |
| Total Equity | 1,004 | 1,214 | 1,691 |
| Operating Margin | 0.00% | 0.00% | 0.00% |
| EPS - Basic | (4.80)p | (2.27)p | (1.44)p |
| EPS - Growth | - | (52.64)% | (36.71)% |
| Dividend Per Share | - | - | - |
| Average Shares Outstanding | 41.43m | 49.64m | 62.93m |
| ROA | (152.34%) | (86.17%) | (55.74%) |
| ROCE | (298.06%) | (110.55%) | (69.95%) |
| ROE | (320.65%) | (101.71%) | (62.31%) |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
31.03.21 (£'000) |
|
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | 106 | - | - |
| Depreciation & Amortisation | 133 | 135 | - |
| Gross Profit | (239) | (135) | - |
| Other Operating Expenses | 1,609 | 1,091 | 1,016 |
| Operating Income (EBIT) | (1,848) | (1,226) | (1,016) |
| Net Interest Expense | - | - | - |
| Unusual Expense (incl. Exceptionals) | - | - | - |
| Non-Operating Expense | (164) | - | - |
| Profit (pre-tax) | (2,012) | (1,226) | (1,016) |
| Taxation | 24 | 98 | 111 |
| Other Expenses and Minortity Interest | - | - | - |
| Net Income | (1,988) | (1,128) | (905) |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
31.03.21 (£'000) |
|
|---|---|---|---|
| Cash from Operations | (2,352) | (518) | (779) |
| Cash from Investing | - | - | - |
| Cash from Financing | 2,386 | 734 | 1,344 |
| Other Miscellaneous | - | - | - |
| Net Cash Flow | 34 | 216 | 565 |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
31.03.21 (£'000) |
|
|---|---|---|---|
| Current Assets | 301 | 601 | 1,201 |
| Non-Current Assets | 926 | 790 | 655 |
| Total Assets | 1,227 | 1,391 | 1,856 |
| Current Liabilities | 223 | 177 | 165 |
| Non-Current Liabilities | - | - | - |
| Total Liabilities | 223 | 177 | 165 |
| Net Assets | 1,004 | 1,214 | 1,691 |
| Total Equity | 1,004 | 1,214 | 1,691 |
Click here to download a glossary of terms.
All data provided by Fregnan.
Address
Business Address
Incanthera plc, 76 King Street, Manchester, M2 4NH, United Kingdom.
Email: suzanne.brocks@incanthera.com
Phone: +44 (0) 161 817 5005
Registered Address
76 King Street, Manchester, M2 4NH, United Kingdom.
Contacts
Corporate Adviser
Cairn Financial Advisers LLP., Cheyne House, Crown Court, 62 - 63 Cheapside, London, United Kingdom.
Phone: +44 (0)20 7148 7900
Registrar
Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom.
Email: info@nevilleregistrars.co.uk
Phone: +44 (0) 121 585 1131